Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-07
2007-08-07
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S396000, C544S370000, C544S367000, C544S360000, C514S254020, C514S255040, C514S253010
Reexamination Certificate
active
10533654
ABSTRACT:
Compounds of general formula (I) wherein R1, R2and R3are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain
REFERENCES:
patent: 3940386 (1976-02-01), Szabo et al.
patent: 5574159 (1996-11-01), Chang et al.
patent: 5681830 (1997-10-01), Chang et al.
patent: 5807858 (1998-09-01), Chang et al.
patent: 5854249 (1998-12-01), Chang et al.
patent: 6130222 (2000-10-01), Roberts et al.
patent: 6680318 (2004-01-01), Brown et al.
patent: 6680321 (2004-01-01), Roberts et al.
patent: 6696447 (2004-02-01), Brown et al.
patent: 6784181 (2004-08-01), Brown et al.
patent: 2431178 (1975-01-01), None
patent: 2900810 (1980-07-01), None
patent: 0133323 (1985-02-01), None
patent: 0166302 (1986-01-01), None
patent: 0283310 (1988-09-01), None
patent: 0289227 (1988-11-01), None
patent: 0624584 (1998-08-01), None
patent: 2696744 (1994-04-01), None
patent: 2076403 (1981-12-01), None
patent: 2210366 (1989-06-01), None
patent: 7-138230 (1995-05-01), None
patent: WO 86/04584 (1986-08-01), None
patent: WO 91/07967 (1991-06-01), None
patent: WO 92/04338 (1992-03-01), None
patent: WO 93/15062 (1993-08-01), None
patent: WO 95/04051 (1995-02-01), None
patent: WO 97/23466 (1997-07-01), None
patent: WO 98/28270 (1998-07-01), None
patent: WO 98/28275 (1998-07-01), None
patent: WO 99/33806 (1999-07-01), None
patent: WO 01/45637 (2001-06-01), None
patent: WO 01/46174 (2001-06-01), None
patent: WO 01/74805 (2001-10-01), None
patent: WO 02/094794 (2002-11-01), None
patent: WO 03/029215 (2003-04-01), None
patent: WO 2004/041800 (2004-05-01), None
patent: WO 2004/041801 (2004-05-01), None
patent: WO 2005/066148 (2005-07-01), None
Bilsky et al., “SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist,” J. Pharmacol. Experi. Ther. 273:359-366 (1995).
Takemori et al., “Selective Natrexone-Drived Opioid Receptor Antagonists,” Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992).
Bilsky et al., “Characterization of Enantiomers of (+) BW373U86 and Related Compounds: Highly Selective Non-Peptidic Delta Opioid Agonists,” Reg. Peptides 54:25-26 (1994).
Calderon et al., “Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of . . . Opioid Receptor Agonist,” J. Med. Chem. 37:2125-2128 (1994).
Calderon et al., “Probes for Narcotic Receptor Mediated Phenomena. 23. Synthesis . . . Opioid Receptor Ligands,” J. Med. Chem. 40:695-704 (1997).
Chang et al., “A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86,” J. Pharmacol. Exper. Therap. 267:852-857 (1993).
Katrizky et al., “Benzotriazole-Mediated Arylalkylation and Heteroarylalkylation,” Chem. Soc. Rev. 23:363-373 (1994).
Kingsbury et al., “Synthesis of Structural Analogs of Leukotriene B and their Receptor Binding Activity,” J. Med. Chem. 36:3308-3320 (1993).
Lopez et al., “Exploring the Structure-Activity Relationships . . . Opioid Receptor Nonpeptide Agonist Ligand,” J. Med. Chem. 42:5359-5368 (1999).
Plobeck et al., “New Diarylmethylpiperazines as Potent and Selective Nonpeptidic Opioid Receptor Agonisits with Increased In Vitro Metabolic Stability,” J. Med. Chem. 43:3878-3894 (2000).
Suggs et al., “Facile Synthesis fo 8-Substituted Quinolines,” J. Org. Chem., 45:1514-1515 (1980).
Zhang et al., “Probes for Narcotic Receptor Mediated Phenomena. 26. Synthesis . . . Opioid Receptor Ligands,” J. Med. Chem. 42:5455-5463 (1999).
English Abstract for Reference B16 on PTO/SB/08A, p. 4.
English Abstract for Reference B17 on PTO/SB/08A, p. 4
English Abstract for Reference B18 on PTO/SB/08, p. 4.
English Abstract for Reference B19 on PTO/SB/08A, p. 4.
Burkey et al., “The Efficacy of Delta-Opioid Receptor-Selective Drugs,” Medline Abstract for Life Sci. 62:1531-1536 (1998).
Nagase et al., “The Pharmacological Profile of Delta Opioid Receptor Ligands, (+) and (−) TAN-67 on Pain Modulation,” Medline Abstract for Life Sci. 68:2227-2231 (2001).
Green, “Protective Groups in Organic Synthesis,” pp. 267-268 and 331 (1981).
Abstract for HU 217619. A corresponding English language PCT application is cited as Reference B1 listed on PTO/SB/08A, p. 1.
Abstract for HU 215847. A corresponding English language PCT application is cited as reference B2 on PTO/SB/08A, p. 1.
Nortey et al., “Piperazinyl Benzamidines: Synthesis and Affinity for the Delta Opioid Receptor,” Bioorganic & Medicinal Chemistry Letters, vol. 11, pp. 1741-1743 (2001).
Snyder et al., “Historical Review: Opioid Receptors,” Trends in Pharmacological Sciences, vol. 24, pp. 198-205 (2003).
Wolff, M.E. et al., “Burger's Medicinal Chemistry and Drug Discovery,” 5ed, Part 1, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al., “Modern Pharmaceutics,” 3ed, Marcel Dekker, New York, 1996, pp. 451 and 596.
West. A.R., “Solid State Chemistry and its Applications,” Wiley, New York, 1988, pp. 358 & 365.
Vippagunta, S.R. et al., “Crystalline Solids,” Advanced Drug Delivery Reviews, vol. 48, 2001, pp. 3-26.
Abstract of Davis, M.P. et al., “Controversies in Pharmacotherapy of Pain Management,” Lancet Oncol., 6(9), 2005, pp. 696-704.
Abstract of Przewlocki, R. et al., “Opioids in Neuropathic Pain,” Curr. Pharm. Des., 11(23), 1995, pp. 2941-2943.
Abstract of Adriaensen, H. et al., “Critical Review of Oral Drug Treatments for Diabetic Neuropathic Pain-Clinical Outcomes Based in Efficacy and Safety Data from Placebo-Controlled and Direct Comparative Studies,” Diabetes Metab. Res. Rev., 21(3), 2005, pp. 231-240.
Brown William
Griffin Andrew
Jones Paul
Page Daniel
Plobeck Niklas
AstraZeneca AB
Berch Mark L.
Cohen Jacqueline M.
Moore Susanna
Shen Jianzhong
LandOfFree
4(Phenyl-piperazinyl-methyl) benzamide derivatives and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3893534